Oslo University Hospital HF

Haematology and Cellular Immunotherapy

Research activity includes follicular lymphoma, multiple myeloma, acute lymphoblastic leukemia, lymphoblastic lymphoma, and graft-versus-host disease, with a strong interest in targeted immune-based treatment strategies and disease monitoring in blood cancers.

  • Follicular lymphoma
  • Multiple myeloma
  • Acute lymphoblastic leukemia
  • Graft-versus-host disease

Additional work spans minimal residual disease-guided treatment, CAR T-cell therapy, and vaccine-based immunotherapy in relapsed or high-risk haematological malignancies.

Solid Tumours and Precision Oncology

The sponsor is active in breast cancer, non-small cell lung cancer, glioblastoma, colorectal cancer, melanoma, esophageal cancer, pancreatic cancer, and malignant pleural mesothelioma, with emphasis on biomarker-informed treatment selection and tumour-directed immunotherapy.

  • Breast cancer
  • Non-small cell lung cancer
  • Glioblastoma
  • Colorectal cancer
  • Melanoma

Clinical interests also include molecularly selected therapy, neoadjuvant treatment, radiotherapy combinations, and personalized tumour profiling.

Neurology, Stroke, and Cognitive Disorders

Trials address acute ischemic stroke, multiple sclerosis, amyotrophic lateral sclerosis, migraine, cognitive impairment, delirium, and autism spectrum disorder, reflecting sustained interest in neurological function, neuroprotection, and symptom control.

  • Acute ischemic stroke
  • Multiple sclerosis
  • Amyotrophic lateral sclerosis
  • Chronic migraine
  • Delirium

Work in this area also covers neural plasticity, post-stroke recovery, and treatment of brain metastases and other central nervous system conditions.

Cardiovascular, Transplantation, and Perioperative Care

Research spans aortic stenosis, arrhythmic mitral valve prolapse, heart transplant, kidney transplantation, kidney failure, and univentricular congenital heart disease, with attention to graft function, rhythm disorders, and cardiovascular support.

  • Aortic stenosis
  • Heart transplant
  • Kidney transplantation
  • Arrhythmic mitral valve prolapse
  • Kidney failure

Additional themes include anticoagulation, hemodynamic management, postoperative delirium, and renal protection in transplant recipients.

Inflammatory, Rare, and Organ-Specific Diseases

The portfolio includes primary sclerosing cholangitis, juvenile idiopathic arthritis, granulomatous lymphocytic interstitial lung disease, venous malformation, frontal fibrosing alopecia, keratolytic winter erythema, and hydrocephalus, showing interest in rare and organ-specific disorders.

  • Primary sclerosing cholangitis
  • Juvenile idiopathic arthritis
  • Granulomatous lymphocytic interstitial lung disease
  • Venous malformation
  • Hydrocephalus

Other areas include ophthalmology, orthopaedics, infectious diseases, and maternal and neonatal care, alongside studies of pain and functional recovery.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Atorvastatin, Placebo, and No Treatment in Adults with Familial Hypercholesterolaemia and Statin-Associated Muscle Symptoms

    Not yet recruiting

    3 1 1
    Investigated drugs:
    Norway
  • Study of lidocaine hydrochloride, ropivacaine, and sodium chloride on acute pain in healthy adults aged 18‑64

    Not yet recruiting

    3 1 1
    Norway
  • A study to evaluate the safety and effectiveness of omalizumab in adults with episodic migraine

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    Norway
  • A study to evaluate the use of tocilizumab in adults with acute ischemic stroke undergoing mechanical clot removal.

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Norway
  • Study of Tenofovir Alafenamide as Add-on Treatment to Anti-CD20 Therapy in Multiple Sclerosis Patients to Reduce Neuronal Damage

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Norway
  • Study of TdT-3 cell therapy safety in patients aged 1 year and older with relapsed or refractory acute leukemia or lymphoblastic lymphoma

    Not yet recruiting

    2 1 1
    Norway